Physician profile
William Andre Duff
NPI 1366446213
$9,411.28
in general payments reported to CMS, 2019-2025
31 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 81% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $821 · 2021: $1,286 · 2022: $1,429 · 2023: $1,381 · 2024: $1,586 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,019 · Education: $95.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,019.15 |
| Education | $95.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,284.37 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals Lp | $1,222.01 | 2019-2025 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $1,070.51 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Amgen INC. | $932.53 | 2019-2025 | Tavneos, Krystexxa, Aranesp |
| Otsuka America Pharmaceutical, INC. | $845.75 | 2019-2025 | Jynarque |
| Travere Therapeutics, INC. | $621.53 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $570.10 | 2021-2025 | |
| Opko Pharmaceuticals, LLC | $488.67 | 2019-2025 | Rayaldee |
| Horizon Therapeutics Plc | $458.88 | 2019-2023 | Krystexxa, Procysbi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.89 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $346.82 | 2019-2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $177.30 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $168.47 | 2021-2025 | Acthar |
| Akebia Therapeutics INC | $155.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $116.42 | 2021-2025 | Benlysta, Arexvy |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $86.17 | 2021-2025 | Lupkynis |
| Nxstage Medical, INC. | $75.69 | 2019-2023 | Nxstage System One, Liberty Select Cycler |
| Calliditas Therapeutics US INC. | $74.34 | 2022-2024 | Tarpeyo |
| Ardelyx, INC. | $51.27 | 2024-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $49.28 | 2022-2023 | Gattex |
| Novo Nordisk INC | $47.49 | 2025 | Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $31.16 | 2019-2020 | |
| Genzyme Corporation | $29.26 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $28.46 | 2021-2023 | |
| Alnylam Pharmaceuticals INC. | $25.32 | 2025 | Givlaari |
| Mallinckrodt Enterprises LLC | $21.59 | 2019 | |
| Shield Therapeutics INC | $18.49 | 2024 | |
| Leadiant Biosciences, INC. | $13.34 | 2020 | |
| Lilly USA, LLC | $13.03 | 2023 | Jardiance |
| Boston Scientific Corporation | $12.09 | 2022 | |
| Janssen Pharmaceuticals, INC | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Duff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.